Description
Healthcare Global Enterprises Limited (BSE: 539787) has fixed March 2, 2026 as the record date for a rights issue offering 1 new equity share for every 17 shares held at Rs 512/- per share (Rs 10 face value + Rs 502 premium).
Summary
Healthcare Global Enterprises Limited (BSE Scrip Code: 539787) has announced a Rights Issue of Equity Shares with a record date of March 2, 2026. Trading in the company’s equity shares must be conducted on an Ex-Rights basis effective from March 2, 2026 (Settlement No. DR-831/2025-2026). The issue offers 1 new equity share for every 17 shares held, priced at Rs 512/- per share.
Key Points
- Company: Healthcare Global Enterprises Limited (BSE Code: 539787)
- Rights ratio: 1 new equity share for every 17 existing equity shares held
- Issue price: Rs 512/- per share (face value Rs 10/- + premium Rs 502/-)
- Record Date: February 28, 2026 (effective ex-rights basis from March 2, 2026)
- Settlement reference: DR-831/2025-2026
- Segment: Dematerialised Securities – Rolling Settlement
- All trading members are instructed to note the ex-rights trading requirement
Regulatory Changes
No new regulatory changes introduced. This circular implements existing SEBI and BSE framework for rights issue corporate actions, requiring mandatory ex-rights trading from the record date.
Compliance Requirements
- Trading Members must execute all transactions in Healthcare Global Enterprises Limited equity shares on an Ex-Rights basis with effect from March 2, 2026.
- Members must update their systems and client communications to reflect the ex-rights adjustment.
- Settlement of transactions must reference DR-831/2025-2026 for the relevant period.
Important Dates
- Record Date: March 2, 2026
- Ex-Rights Trading Effective From: March 2, 2026
- Settlement Number: DR-831/2025-2026
- Circular Date: February 25, 2026
Impact Assessment
Existing shareholders of Healthcare Global Enterprises Limited as of the record date (March 2, 2026) will be entitled to subscribe to 1 new equity share for every 17 shares held at Rs 512/- per share. The rights issue will dilute existing shareholding by approximately 5.88% upon full subscription. Trading members must adjust order entry and pricing from the ex-rights date to avoid settlement mismatches. The premium of Rs 502/- over the Rs 10/- face value reflects the current market valuation of the company. Shareholders who do not subscribe may see proportional dilution of their holdings.
Impact Justification
Rights issue directly affects existing shareholders' holdings and requires trading members to execute transactions on an ex-rights basis from the record date, with immediate pricing and eligibility implications for all holders.